about
In vivo studies of Gd-DTPA-monoclonal antibody and gd-porphyrins: potential magnetic resonance imaging contrast agents for melanoma.Non Invasive XRF Analysis of Human Hair for Health State Determination of Breast Tissue.Superparamagnetic iron oxide-C595: Potential MR imaging contrast agents for ovarian cancer detection.The effect of continuous ELF-MFs on the level of 5-HIAA in the raphe nucleus of the rat.Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer.Assessment of entrance surface dose and health risk from common radiology examinations in Iran.The Radioprotective Effect of Resveratrol Against Genotoxicity Induced by γ-Irradiation in Mice Blood Lymphocytes.Photoneutron contamination from an 18 MV Saturne medical linear accelerator in the treatment room.Evaluation of the Effects of Prostate Radiation Therapy on Occludin Expression and Ultrasonography Characteristics of the Bladder.natural background radiation dosimetry in the highest altitude region of Iran.Versatile theranostics agents designed by coating ferrite nanoparticles with biocompatible polymers.Detection of MUC1-expressing ovarian cancer by C595 monoclonal antibody-conjugated SPIONs using MR imaging.Quantitative analysis of left ventricular performance from sequences of cardiac magnetic resonance imaging using active mesh model.Gold nanoparticles in combination with megavoltage radiation energy increased radiosensitization and apoptosis in colon cancer HT-29 cells.Evaluation of Targeted Image-Guided Radiation Therapy Treatment Planning System by Use of American Association of Physicists in Medicine Task Group-119 Test Cases.Mobile phone radiation interferes laboratory immunoenzymometric assays: Example chorionic gonadotropin assaysAS1411 aptamer-targeted gold nanoclusters effect on the enhancement of radiation therapy efficacy in breast tumor-bearing miceAnti-CD24 bio Modified PEGylated Gold Nanoparticles as Targeted Computed Tomography Contrast AgentEffect of livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimenEvaluation of the Radiosensitizing Potency of Bromelain for Radiation Therapy of 4T1 Breast Cancer CellsThe effect of gel homogeneity on dose response in a low-density polymer gel dosimeter for radiation therapyEssential considerations for accurate evaluation of photoneutron contamination in RadiotherapySynthesis and characterisation of iron oxide nanoparticles conjugated with epidermal growth factor receptor (EGFR) monoclonal antibody as MRI contrast agent for cancer detection
P50
Q30657508-DA41867E-8885-4132-AAF6-07BF70E59963Q36529349-2AA9A7C5-C60F-454C-A4E0-FC6A3A65DCFBQ37645860-BCA7A80B-9301-460F-BF55-C0EC41D784D3Q39102671-E1C2FAA4-8612-4BB8-B7D2-35E94F020B1CQ39217780-9DCC7AE6-C229-41ED-A1BD-EF3229C31046Q39552879-550B2FC1-44B6-451D-8A8C-E9C0E77B4693Q41881029-1965C98E-4EAB-47E8-B866-25DC5C3AC090Q45175387-454C93B9-3B65-4D21-85CC-3EA0A0ED4F6EQ47795642-80B6E19D-0C91-452B-A839-15A782D3EF0EQ50734268-15F02E7E-075F-41A2-A0F6-24034CA6A59EQ51329936-1486BAC7-934D-4950-81EE-C7AC17D5C957Q51773840-5DC0D45D-F4E1-44BE-8721-C84CE78413ACQ51852825-539C9A96-DDE5-4477-8C37-23B55ED25C35Q52839198-BE3BC7BA-5987-4953-8114-7A1AB15343F8Q55279465-4A9834B1-3976-40B3-BFB0-7251EC68CACCQ57753539-BFB19E7C-F7F9-4ABA-9026-FD03D58BBE74Q58598768-8B4B4E43-60B9-447C-87C2-09FE36168342Q60925836-370AADDF-F7CD-48A8-A3F0-42244F5EA058Q61454166-A2C5B7E3-6E49-49B3-A340-F3FBDCB8A931Q64266721-1037269D-C2BB-45EF-8005-E1093DA3F82AQ89074311-448A6B4A-1B73-40C8-B19F-D595A23D45BBQ90673065-04E30138-33CD-44B1-B08A-97B6978A362CQ95503461-2F20B1E1-3671-4814-9449-4F68D1B61C96
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daryoush Shahbazi-Gahrouei
@ast
Daryoush Shahbazi-Gahrouei
@en
Daryoush Shahbazi-Gahrouei
@es
Daryoush Shahbazi-Gahrouei
@nl
Daryoush Shahbazi-Gahrouei
@sl
type
label
Daryoush Shahbazi-Gahrouei
@ast
Daryoush Shahbazi-Gahrouei
@en
Daryoush Shahbazi-Gahrouei
@es
Daryoush Shahbazi-Gahrouei
@nl
Daryoush Shahbazi-Gahrouei
@sl
prefLabel
Daryoush Shahbazi-Gahrouei
@ast
Daryoush Shahbazi-Gahrouei
@en
Daryoush Shahbazi-Gahrouei
@es
Daryoush Shahbazi-Gahrouei
@nl
Daryoush Shahbazi-Gahrouei
@sl
P106
P1153
6507450935
P31
P496
0000-0002-8538-1898